Low-dose Cortisol in Chronic Posttraumatic Stress Disorder
Not Applicable
Terminated
- Conditions
- Posttraumatic Stress Disorder
- Registration Number
- NCT00362661
- Lead Sponsor
- University of Zurich
- Brief Summary
The aim of this prospective, double-blind, placebo-controlled, cross-over study is to determine the therapeutic efficacy of low-dose cortisol for symptoms of chronic posttraumatic stress disorder.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Female and male patients with chronic PTSD due to adult trauma; PTSD is diagnosed according to the DSM-IV, as measured with the CAPS
- Age between 18 and 60
Exclusion Criteria
- History of disease states representing contraindications to glucocorticoid therapy (tuberculosis, gastritis, gastric- and duodenal ulcers, Cushing's disease, osteoporosis, hypertension, pregnancy (to exclude with a pregnancy test) and lactation, glaucoma, diabetes mellitus, thrombophilia, acute or chronic infections, hyperthyroidism, cirrhosis)
- Severe or chronic somatic diseases
- Topic glucocorticoid therapy (for large skin parts)
- Inhaled glucocorticoids
- Current psychotic, bipolar, substance-related, or severe personality disorder
- Current severe depressive disorder
- Severe cognitive impairment or a history of organic mental disorder
- Evidence of PTSD or depression immediately prior to the index trauma
- Prominent current suicidal or homicidal ideation
- Asylum seeking status
- Body weight >20% above or below normal range
- Changes in psychopharmacologic or psychotherapeutic management less than 8 weeks before start of the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method CAPS CGI 1 year
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Department of Psychiatry, University Hospital Zurich
🇨ðŸ‡Zurich, Switzerland